CHECKLIST FOR PLANNING AND RUNNING SCHOOL FLU VACCINATION DAYS

Share good times not flu IN SCHOOLS

NHS CHILDHOOD SEASONAL FLU IMMUNISATION PROGRAMME

Flu vaccination in school children:

- For all school children in Reception to Year 7 in England*[1]
- There may be some variance across the UK within the other devolved nations*

A guide to accessing online resources for Immunisation Teams

RCN-accredited online learning modules available at: www.fluenztetra.co.uk/training

Fluenz Tetra
nasal spray, suspension influenza vaccine
(live attenuated, nasal)

* Please check the respective communications for Wales, Northern Ireland and Scotland. Age eligibility as of 31st August 2020.

The content of this leaflet is intended for UK school nurses, immunisation teams and school healthcare professionals only.
The content is to be used as a guide and is not a substitute for clinical judgement.

Prescribing Information can be found on the last page.

Produced and provided by AstraZeneca

Flu vaccination day planning checklist

Check the following have been completed well in advance of the vaccination day:

- **Ensure the vaccine administrator(s) are trained**
- **Ensure that adequate measures are in place to allow social distancing and that hand washing/sanitisation facilities are available**
- **Review and assess available resources and information for teachers, parents/carers and pupils:** www.sharegoodtimesnotflu.co.uk/toolkit
- **Consent:**
  - Agree with the wider school team how and when the consent forms will be supplied
  - Ensure parents and carers have been informed of the purpose of the flu vaccination programme and of procedures for giving consent
  - Translation of consent forms may need to be organised
  - Consider that some parents may not have online access
  - Distribute, and have consent forms returned, as early as possible
  - Provide the consent form with a supporting letter or note outlining further information and sources of advice
  - Set up a reminder system
  - Consider running drop-in sessions or parents' information evenings
  - Prepare a strategy for 'on-the-day' consent withdrawal
- **Encourage the engagement of faith and community leaders where possible to help reinforce positive health messages**
- **Secure a room or hall large enough to set up separate stations to allow groups of pupils to be vaccinated**
- **Consider alternative options, such as drive through clinics, should local social distancing measures require**
- **Staff:**
  - Ensure a member of staff is assigned to monitor pupils queuing and calm any last-minute anxieties
  - Identify a member of staff to act as 'runner', bringing new classes into the queue
  - Inform teachers/assistants that they may be asked to confirm the identity of younger pupils
- **Promote the date! Use Schools Toolkit materials on the SGTNF website and other eye catching materials to create awareness of dates and timings**
- **Organise:**
  - Parking for the healthcare team
  - Healthcare team IDs
  - Point of contact for the healthcare team
  - Space for the healthcare team to take a break
  - Desks and chairs for the healthcare team/children
  - Immunisation equipment
  - Administration paperwork
  - Supply of tissues
  - Posters around the school as a reminder for timings
  - Personal Protective Equipment for staff and healthcare team, and hand sanitiser
  - Guidance and signage for social distancing

Flu vaccination day checklist

Use this checklist on the vaccination day itself:

- Lists of eligible children for whom consent has been received
- Staff members monitoring the queue, acting as runners are available as planned
- Parking for the healthcare team
- Healthcare team IDs
- Point of contact for the healthcare team
- Space for the healthcare team to take a break
- Desks and chairs for the healthcare team/children
- Immunisation equipment
- Administration paperwork
- Supply of tissues
- Personal Protective Equipment for staff and healthcare team, and hand sanitiser
- Clear social distancing signage

Produced and provided by

AstraZeneca

Prescribing Information

FLUENZ® TETRA nasal spray suspension Influenza vaccine (live attenuated, nasal)

Consult Summary of Product Characteristics before prescribing.

Indication: Prophylaxis of influenza in individuals 24 months to less than 18 years of age. **Presentation:** Nasal spray, suspension. **Dosage and administration:** 0.2ml (administered as 0.1ml per nostril). Children not previously vaccinated against seasonal influenza should be given a second dose after an interval of at least 4 weeks. Should not be used in individuals below 24 months of age because of safety concerns. *Method of administration:* Nasal administration only. **Do not inject Fluenz Tetra. Contraindications:** Hypersensitivity to the active substances, any of the excipients (e.g. gelatin), gentamicin (a possible trace residue). Severe allergic reaction (e.g. anaphylaxis) to eggs or to egg proteins (e.g. ovalbumin). Children and adolescents who are clinically immunodeficient due to conditions or immunosuppressive therapy: (acute and chronic leukaemias; lymphoma; symptomatic HIV infection; cellular immune deficiencies; and high-dose corticosteroids). Not contraindicated for use in individuals with asymptomatic HIV infection; or individuals who are receiving topical/inhaled corticosteroids or low-dose systemic corticosteroids or those receiving corticosteroids as replacement therapy, e.g. for adrenal insufficiency. Contraindicated in children and adolescents younger than 18 years of age receiving salicylate therapy because of the association of Reye's syndrome with salicylates and wild-type influenza infection. **Warnings and precautions:** Clearly record name and batch number of administered product to improve traceability. Medical treatment and supervision should always be readily available in case of an anaphylactic event following administration. Fluenz Tetra should not be administered to children and adolescents with severe asthma or active wheezing because these individuals have not been adequately studied in clinical studies. Do not administer to infants and toddlers below 24 months of age because of safety concerns regarding increased rates of hospitalisation and wheezing in this population. Vaccine recipients should be informed that Fluenz Tetra is an attenuated live virus vaccine and has the potential for transmission to immunocompromised contacts. Vaccine recipients should attempt to avoid, close association with severely immunocompromised individuals (e.g. bone marrow transplant recipients requiring isolation) for 12 weeks following vaccination. Where contact is unavoidable, the potential risk of transmission of the influenza vaccine virus should be weighed against the risk of acquiring and transmitting wild-type influenza virus. No data exists regarding the safety in children with unrepaired craniofacial malformations. Drug interactions: Salicylates must not be used for 4 weeks following vaccination unless medically indicated. Co-administration of trivalent Fluenz with the live attenuated vaccines: No clinically meaningful changes in immune responses to measles, mumps, varicella, orally-administered poliovirus or trivalent Fluenz have been observed. Immune response to rubella vaccine was significantly altered. This might not be of clinical relevance with the two dose immunisation schedule of the rubella vaccine. Fluenz Tetra (influenza vaccine-live attenuated, nasal) is identical to trivalent Fluenz with the only difference being the addition of a fourth strain (a second B strain) to Fluenz Tetra. Co-administration of Fluenz Tetra with inactivated vaccines has not been studied. Concurrent use with antiviral agents active against influenza A and/or B viruses has not been evaluated. Based upon the potential for influenza antiviral agents to reduce the effectiveness of Fluenz Tetra, it is recommended not to administer the vaccine until 48 hours after the cessation of influenza antiviral therapy. Administration of influenza antiviral agents within two weeks of vaccination may affect the response of the vaccine. If influenza antiviral agents and Fluenz Tetra are administered concomitantly, revaccination should be considered based on clinical judgment. Fertility, Pregnancy and Lactation: Not recommended during pregnancy. Should not be used during breast-feeding. No data on the effects of Fluenz Tetra on male and female fertility. **Undesirable effects:** Refer to SmPC for complete information on side effects. Very common: decreased appetite, nasal congestion/rhinorrhoea, malaise. Common: headache, myalgia, pyrexia. Uncommon: hypersensitivity reactions (including facial oedema, urticaria and very rare anaphylactic reactions), epistaxis, rash. Very rare reports of Guillain-Barré syndrome and exacerbation of symptoms of Leigh syndrome (mitochondrial encephalomyopathy) have also been observed in the post-marketing setting. **Legal category:** POM. **Marketing authorisation number:** EU/1/13/887/004 **Presentation & basic NHS cost:** Fluenz Tetra nasal spray suspension pack of 10: £180.00 **Marketing Authorisation Holder:** AstraZeneca AB, SE-151 85 Södertälje, Sweden **Further information is available from:** AstraZeneca UK Limited, 600 Capability Green, Luton, LU1 3LU, UK.

Date of preparation: 03/2020
INF 20 0002

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting https://aereporting.astrazeneca.com or by calling 0800 783 0033.

Reference: 1. Whitty C, Doyle Y & Powis S. The national flu immunisation programme 2020 to 2021- update. 05 August 2020. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/907149/Letter_annualflu_2020_to_2021_update.pdf.

Produced and provided by
AstraZeneca